[Pubmed] Pathogenesis of MuSK Antibody-positive Myasthenia Gravis
Posté : 08 janv. 2024 12:00
Brain Nerve. 2024 Jan;76(1):47-53. doi: 10.11477/mf.1416202557.
ABSTRACT
Long-term remission is rare in patients with myasthenia gravis (MG), and health-related quality of life is lower in patients with MG than in healthy individuals. Approximately 5% of patients with MG show positive results on muscle-specific kinase (MuSK) antibody testing and usually have severe symptoms, refractory disease, residual muscle atrophy, and poor prognosis. Recent studies that have investigated the pathogenesis of MuSK antibody-positive MG have reported contributors to treatment refractoriness in cases of MG. In this article, we review the most recent findings.
PMID:38191139 | DOI:10.11477/mf.1416202557
Source: https://pubmed.ncbi.nlm.nih.gov/3819113 ... 9&v=2.18.0